In-Depth Analysis: WDB COCO (7079) Q1 FY2027 Earnings – Declining Case Volumes and the Roadmap for Structural Reform and Growth

This report provides a multi-faceted analysis of the Q1 FY2027 earnings for WDB COCO Co., Ltd. (Ticker: 7079), covering financial performance, cost structures, business models, full-year forecasts, growth strategies, and shareholder return policies.

---

1. Executive Summary: Overview of Q1 FY2027 Results

WDB COCO reported a decline in both revenue and profit for the first quarter (Q1) of the fiscal year ending March 2027 compared to the same period last year. However, performance remains within the scope of the company's initial projections.

• Revenue : ¥1,153 million (down 8.3% YoY)
• Operating Profit : ¥199 million (down 14.9% YoY)
• Ordinary Profit : ¥199 million (down 15.1% YoY)
• Quarterly Net Income (EPS) : ¥137 million / ¥57.3 (down 15.8% YoY)

The primary driver for the revenue decline was a decrease in the number of adverse event cases reported by certain clients within the core "Safety Information Management Service." Nevertheless, the steady operation of additional and new projects, combined with rigorous optimization and control of labor and SG&A expenses, prevented a significant margin compression and maintained stable profitability. The full-year earnings forecast remains unchanged.

Importance of the Summary Slide and Data Analysis

The summary slide above is the most critical document for grasping the overall P&L picture and the factors behind the change in ordinary profit (waterfall chart) for the Q1 results. Looking at the transition from ¥235 million in ordinary profit in the same period last year to ¥199 million this term, the data shows that while the decline in revenue exerted downward pressure on profits (down ¥104 million) , this was largely offset by cost optimization, including improvements in labor costs (+¥63 million) and personnel expense management (+¥10 million) . This structure highlights the company's ability to maintain high profitability, with both operating and ordinary profit margins holding steady at 17.3% .

---

2. Quarterly Performance Trends and Cost Control Structure

(1) Revenue Fluctuations and Quarterly Trends

Revenue decreased by ¥104 million (down 8.3%) YoY. Looking at historical quarterly trends, revenue peaked at ¥1,387 million in Q3 FY2025 and has since fluctuated in the ¥1.1 billion to ¥1.2 billion range since Q1 FY2026 (¥1,257 million). The core Safety Information Management Service was impacted by changes in pharmaceutical companies' product portfolios and trends in post-marketing data generation. Conversely, the company has partially offset these declines through deepening proposals to existing clients and securing new document support projects .

(2) Gross Profit and Cost of Sales (Labor Costs)

• Gross Profit : ¥388 million (down 10.6% YoY)
• Gross Profit Margin : 33.7% (down 0.9pt YoY)

While utilization rates temporarily dipped as the company maintained a certain headcount in anticipation of future order growth and new project launches, the company enforced strict labor cost controls, such as optimizing overtime work and managing recruitment activities . This kept the increase in the cost-to-sales ratio to a minimum (up 0.9pt).

(3) SG&A Expense Control and Operating Profit

• Operating Profit : ¥199 million (down 14.9% YoY)
• Operating Profit Margin : 17.3% (down 1.4pt YoY)

SG&A expenses totaled ¥188 million , a ¥11 million (approx. 5.5%) reduction from the same period last year (¥199 million). Although this was insufficient to fully compensate for the decline in gross profit, continuous efforts toward operational efficiency and expense control have provided a floor for profit margins.

---

3. WDB COCO’s Business Model and Unique Position in the CRO Industry

WDB COCO is a CRO (Contract Research Organization) that provides services ranging from pharmaceutical and medical device development to the post-marketing phase. The company’s strength and revenue base lie in its specialization in the "post-marketing phase (drug maturation process)."

Importance of the Slide (Company Positioning in CRO Support) and Data Analysis

The slide above is crucial for understanding the structural advantages of the company's business model . Typical CRO tasks during the clinical trial phase (monitoring, data management, etc.) are "fixed-term tasks" that arise and conclude with each development project. In contrast, WDB COCO’s core service, "Safety Information Management Service (PV: Pharmacovigilance)," is a "perpetual task (stock-type business)" that arises legally as long as pharmaceutical companies continue to sell their products in the market. This stock-type business structure is the foundation that allows the company to avoid sharp performance deterioration and maintain high profitability (17% range) even during temporary declines in case volumes or project transitions.

---

4. Full-Year FY2027 Earnings Forecast and Growth Strategy

(1) Progress Toward Full-Year Forecast

The full-year consolidated earnings forecast for FY2027 remains unchanged from the initial announcement.

Item	Q1 FY2027 Actual	Full-Year Forecast	Q1 Progress
Revenue	¥1,153 million	¥4,655 million	24.8%
Operating Profit	¥199 million	¥960 million	20.8%
Ordinary Profit	¥199 million	¥967 million	20.7%
Net Income	¥137 million	¥680 million	20.3%

The revenue progress rate is 24.8% , nearly reaching the standard (25%), and profit items are also progressing steadily at just over 20%, which is within the expected range .

Importance of the Slide (Earnings Forecast) and Data Analysis

This slide illustrates the growth story and initiatives regarding how the company views the current revenue decline and what countermeasures it will take for the latter half of the year. The company set its full-year forecast with the prior assumption that the decline in case volumes for the core Safety Information Management Service would continue to some extent. To drive recovery and renewed growth, the company plans to promote the following three key initiatives :

1. Promotion of Structural Reform : Eliminate reliance on individual expertise by pushing for the standardization and automation of business processes, dramatically improving service quality consistency and productivity.
2. Redefining Value and Expanding New Orders : Redefine and reconstruct the value proposition of traditional document support services to strengthen proposal capabilities to pharmaceutical companies and secure new orders.
3. Deepening Existing Client Relationships : Accelerate the cross-selling of safety information management and document support services to other departments or new drug lines within existing clients.

---

5. Shareholder Return Policy and Financial/Equity Foundation

(1) Strengthening Dividend Policy and High Return Levels

While WDB COCO previously prioritized internal reserves for growth investment, it has shifted toward a policy of accelerating corporate value enhancement and shareholder returns.

• FY2027 Forecast Dividend : ¥100.00 per share (expected increase from ¥95.00 in the previous year)
• Forecast Payout Ratio : 35.4%
• Forecast DOE (Dividend on Equity) : 5.0%

Looking at historical trends, the company has consistently increased dividends from ¥34.00 in FY2020. By setting a clear indicator of a 5.0% DOE, the company demonstrates a stable shareholder return stance that is less susceptible to short-term fluctuations in performance.

(2) Shareholder Composition and Management Foundation

As of the end of March 2026, the parent company, WDB Holdings Co., Ltd., holds 67.7% of the shares, providing a stable group management foundation. The company also continues its IR efforts aimed at increasing the ratio of institutional and individual investors.

---

6. Conclusion and Future Focus Points

Although WDB COCO’s Q1 FY2027 results showed a decline in revenue and profit YoY, the company maintained a stable performance with a high profit margin exceeding 17% , thanks to the characteristics of its business model (stock-type) and rigorous cost control.

Future Focus Points :

1. Productivity Gains from Automation/Standardization : To what extent will the promotion of structural reform and automation contribute to the improvement of the gross profit margin from Q2 onwards?
2. Pace of New Order Acquisition : Progress in acquiring new clients and projects through the redefinition of value propositions.
3. Bottoming Out and Recovery of Case Volumes : When will the downward trend in adverse event cases at major clients stabilize and head toward recovery?

The market will be watching how WDB COCO proceeds with its structural reforms while adapting to the changing environment and how its business performance evolves.